Cytopia Commences Phase II Cancer Drug Study
Cytopia has obtained regulatory approval to proceed with a Phase II clinical study assessing its lead anti-cancer drug in up to 24 multiple myeloma patients. Patient enrolment will soon commence.
Share this content.
If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.